Veradermics Analyst Price Targets - Benzinga

Veradermics Inc

MANENYSE

Trade with Public

Trade with Public

$143.50

-0.34-0.24%

마지막 업데이트: Oct 30, 10:46 AM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 주식 보고서

Veradermics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Veradermics (MANE).

Price Target Range — 4 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$157Upside to Avg. PT+9.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 22, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$170→$204
Oct 19, 2026	Cantor Fitzgerald	Prakhar Agrawal	Maintained	Overweight	—
Oct 19, 2026	Needham	Serge Belanger	PT Raise	Buy	$164→$172
Jul 16, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$135→$160
Jul 15, 2026	Needham	Serge Belanger	PT Raise	Buy	$136→$164
Jul 15, 2026	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$170
Jul 7, 2026	Jefferies	Roger Song	PT Raise	Buy	$138→$182
Jun 16, 2026	LifeSci Capital	Rami Katkhuda	Initiate	Outperform	$135
Jun 2, 2026	Needham	Serge Belanger	Initiate	Buy	$136
May 18, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$120→$135
Apr 22, 2026	Leerink Partners	Marc Goodman	PT Raise	Outperform	$75→$90
Mar 2, 2026	Cantor Fitzgerald	Prakhar Agrawal	Initiate	Overweight	—
Mar 2, 2026	Citigroup	Geoff Meacham	Initiate	Buy	$85
Mar 2, 2026	Leerink Partners	Marc Goodman	Initiate	Outperform	$75
Mar 2, 2026	Jefferies	Roger Song	Initiate	Buy	$75

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204

B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.

Benzinga Newsdesk

Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday

Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.

Avi Kapoor

PRO
Cantor Fitzgerald Reiterates Overweight on Veradermicsto Overweight

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Veradermics (NYSE:MANE) from Overweight to Overweight.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Veradermics, Raises Price Target to $172

Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $164 to $172.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Veradermics, Raises Price Target to $160

Citigroup analyst Geoff Meacham maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $135 to $160.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Veradermics, Raises Price Target to $164

Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $136 to $164.

Benzinga Newsdesk